WO2012121810A1 - Appareil permettant de distinguer une tachycardie supraventriculaire d'une tachycardie ventriculaire au moyen d'une stimulation myocardique focale - Google Patents

Appareil permettant de distinguer une tachycardie supraventriculaire d'une tachycardie ventriculaire au moyen d'une stimulation myocardique focale Download PDF

Info

Publication number
WO2012121810A1
WO2012121810A1 PCT/US2012/022505 US2012022505W WO2012121810A1 WO 2012121810 A1 WO2012121810 A1 WO 2012121810A1 US 2012022505 W US2012022505 W US 2012022505W WO 2012121810 A1 WO2012121810 A1 WO 2012121810A1
Authority
WO
WIPO (PCT)
Prior art keywords
ventricular
response
atrial
event
fast
Prior art date
Application number
PCT/US2012/022505
Other languages
English (en)
Inventor
Yong-Fu Xiao
Jeffrey M. Gillberg
Paul J. Degroot
Eduardo N. Warman
Scott J. Brabec
John L. Sommer
Jon F. Urban
Lepeng Zeng
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority claimed from US13/357,659 external-priority patent/US20120232606A1/en
Publication of WO2012121810A1 publication Critical patent/WO2012121810A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362—Heart stimulators
    • A61N1/3621—Heart stimulators for treating or preventing abnormally high heart rate
    • A61N1/3622—Heart stimulators for treating or preventing abnormally high heart rate comprising two or more electrodes co-operating with different heart regions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/346—Analysis of electrocardiograms
    • A61B5/349—Detecting specific parameters of the electrocardiograph cycle
    • A61B5/361—Detecting fibrillation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/346—Analysis of electrocardiograms
    • A61B5/349—Detecting specific parameters of the electrocardiograph cycle
    • A61B5/363—Detecting tachycardia or bradycardia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/39—Heart defibrillators
    • A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
    • A61N1/3962—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion in combination with another heart therapy
    • A61N1/39622—Pacing therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/377—Electroencephalography [EEG] using evoked responses

Definitions

  • This disclosure relates generally to implantable medical devices and, specifically, to cardiac electrical stimulation and discrimination of cardiac arrhythmias. 0 BACKGROUND
  • ICDs implantable cardioverter defibrillators
  • VT sustained ventricular tachycardia
  • Unnecessary ICD shocks cause undue pain, psychological disturbance and can potentially induce more serious arrhythmias in some patients.
  • Supraventricular tachycardia SVT
  • atrial fibrillation atrial tachycardia
  • sinus tachycardia sinus tachycardia
  • ICD shocks due to SVT being detected as VF or VT can account for some shocks delivered to ICD- implanted patients. Therefore, appropriately distinguishing SVT from VT could lead to a reduction in unecessary ICD shocks being delivered, without decreasing ICD efficacy.
  • FIG. 1 depicts an implanted, multi-channel ICD according to one embodiment for use in detecting cardiac arrhythmia episodes and delivering arrhythmia therapy when appropriate.
  • FIG. 2 is a functional block diagram of the ICD 14 shown in FIG. 1 ,
  • FIG. 3 is a functional flowchart 100 illustrating the operation of an ICD practicing one embodiment for arrhythmia discrimination.
  • FIG. 4 is a flow chart 200 of an alternative embodiment of a method for discriminating cardiac events.
  • the sino-atrial (SA) node initiates action potentials which propagate to the whole heart via a conductive system.
  • the SA node, atria and atrio-ventricular (AV) node are normally excited earlier and recover earlier in the cardiac cycle than the ventricles.
  • the refractory period of the ventricles continues after the end of the atrial and nodal refractory periods due to longer action potential durations associated with the ventricular myocardium. Therefore, there is a stimulus time window during which the atrial myocardial tissue, SA node and/or AV node, referred to herein collectively as "atrial tissue", may be excited while the ventricles remain refractory to stimulation.
  • the stimulation of the SA node or AV node in the methods described herein is achieved via inducing myocardial cell depolarization in contrast to modulating nodal tissue excitability via stimulating the nerves that innervate the nodal tissue.
  • Excitation of the atria, SA node and/or AV node during the ventricular refractory period resets the atrial cycle (resets the SA node) and starts a new refractory period in the atrial and AV nodal tissue, without triggering a ventricular contraction.
  • the result is that propagation of a depolarization to the ventricles effective to cause a contraction is delayed until the next subsequent
  • the inventors have found that delivery of electrical stimulation to atrial tissue during SVT can effectively reset the SA node or block the AV node impulse propagating to the ventricles, resulting in a slowing of up to 50% of the ventricular rate in experimental subjects. In some cases, an SVT can even be terminated by a properly timed atrial stimulus pulse.
  • the slowing of the ventricular rate during SVT, or termination of SVT allows the SVT to be reliably discriminated from VT since the atrial tissue stimulation will have no effect on the ventricular rate if the fast ventricular rate is originating in the ventricular chambers.
  • the slowing of the ventricular rate by depolarizing atrial myocardial tissue during ventricular refractory to enable tachycardia discrimination thus has the potential to reduce ICD shocks delivered unnecessarily during SVT.
  • the delivered atrial stimulus pulses may correspond to typical cardiac pacing pulses or may be pulse bursts having burst envelopes corresponding to the duration and/or morphology of normal cardiac pacing pulses. Longer pulse durations, e.g. 10 ms or more may also be employed. The particular form of the pulse is not critical so long as it triggers a depolarization of the desired atrial tissue. Proper timing of the stimulus pulses within the defined excitation window is important to assure that the desired effect is produced, i.e. atrial myocardial depolarization during ventricular refractory, without induction of arrhythmias.
  • the stimulus time window extends from the point at which the atrial tissue to be stimulated becomes non-refractory up to the point at which the stimulated atrial depolarization could propagate to the ventricles to cause a ventricular depolarization.
  • the time window will vary from patient to patient, but generally will fall between the end of the atrial refractory period and the end of the ventricular refractory period.
  • the window generally thus extends within a time period occurring between about 80 ms to about 200 ms following a normally conducted ventricular depolarization, or more or less depending on the instant heart rate.
  • Refractory period timing and durations may vary with the individual and with the underlying heart rhythm, and thus the duration of the time window will also vary. Timing of the stimulus pulses may be based upon a preceding atrial
  • Timing of the stimulus pulses may be predefined by the attending physician and programmed into the device.
  • Timing of the stimulus may also be based on a patient-specific look-up table of values dependent on physiologic variables such as heart rate, QT interval or AV interval. These patient specific values may be based on values established at baseline (rest) with empirically derived linear or non-linear extrapolations based on prior measurements, or these values could be established based on AV or QT timing measurements at various heart rates during a "learning period" in a given patient.
  • the location of the stimulus pulse delivery can also be important in effectively resetting the SA node or causing AV node block before the next intrinsic atrial depolarization arises from the SA node and conducts to the AV node.
  • placement of the lead(s) and electrodes for stimulating the atrial tissue will be important.
  • a stimulus pulse delivered at an atrial electrode site needs to depolarize the atrial myocardial tissue and propagate to the SA node to cause a resetting of the SA node before the SA node initiates the next intrinsic beat and/or reach the AV node to block a next atrial depolarization from
  • the timing and the location of the atrial tissue stimulus is selected to promote delivery of the stimulus during the ventricular refractory period and outside of the atrial refractory period such that the evoked atrial depolarization has adequate time to propagate to the SA node and/or AV node before the next intrinsic depolarization arises from the SA node.
  • An electrode delivering the atrial tissue stimulus pulse may be located in close proximity, therefore, to either the SA node or the AV node.
  • heart 10 includes the upper heart chambers, the right atrium (RA) and left atrium (LA), and the lower heart chambers, the right ventricle (RV) and left ventricle (LV) and the coronary sinus (CS) extending from the opening in the right atrium laterally around the atria to form the great vein that extends further inferiorly into branches of the great vein.
  • the cardiac cycle commences normally with the generation of the depolarization impulse at the SA node in the right atrial wall. The impulse then conducts through the right atrium, to the left atrial septum and reaches the AV node and the atrial septum within about 40 ms and the furthest walls of the RA and LA within about 70 ms.
  • the aggregate RA and LA depolarization wave appears as the P-wave of the PQRST complex when sensed across external ECG electrodes and displayed.
  • the component of the atrial depolarization wave passing between a pair of unipolar or bipolar pace/sense electrodes, respectively, located on or adjacent the RA or LA is also referred to as a sensed P-wave.
  • the depolarization impulse that reaches the AV node conducts down the bundle of His in the intra-ventricular septum after a delay of about 120 ms.
  • the depolarization wave reaches the apical region of the heart about 20 ms later and then travels superiorly though the Purkinje fiber network over the remaining 40 ms.
  • the aggregate RV and LV depolarization wave and the subsequent T-wave accompanying re-polarization of the depolarized myocardium are referred to as the QRST portion of the PQRST cardiac cycle complex when sensed across external ECG electrodes and displayed.
  • FIG 1 depicts an implanted, multi-channel ICD according to one embodiment for use in detecting cardiac arrhythmia episodes and delivering arrhythmia therapy when appropriate.
  • the ICD 14 is implanted subcutaneously in a patient's body between the skin and the ribs.
  • Three transvenous leads 16, 32 and 52 connect the ICD 14 with the RA, the RV and the LA and LV, respectively.
  • Each lead has at least one electrical conductor and pace/sense electrode, and a remote indifferent can electrode 20 is formed as part of the outer surface of the housing of the ICD 14.
  • the pace/sense electrodes and the remote indifferent can electrode 20 can be selectively employed to provide a number of unipolar and bipolar pace/sense electrode combinations for pacing and sensing functions.
  • the depicted positions in or about the right and left heart chambers are merely illustrative.
  • other leads and pace/sense electrodes may be used instead of the depicted leads and pace/sense electrodes that are adapted to be placed at electrode sites on or in or operative relation to the RA, LA, RV and LV.
  • the depicted bipolar endocardial RA lead 16 is passed through a vein into the RA chamber of the heart 10, and the distal end of the RA lead 16 is attached to the RA wall by an attachment mechanism 17.
  • the distal end of the lead 16 is located near the AV node or in the right atrial appendage, although other locations may be substituted in some cases.
  • the bipolar endocardial RA lead 16 is formed with an in-line connector 13 fitting into a bore of ICD connector block 12 that is coupled to electrically insulated conductors within lead body 15 and connected with distal tip RA pace/sense electrode 19 and proximal ring RA pace/sense electrode 21 .
  • Atrial pace pulses and sensing of atrial sense events is effected between the distal tip RA pace/sense electrode 19 and proximal ring RA pace/sense electrode 21 , wherein the proximal ring RA pace/sense electrode 21 functions as an indifferent electrode (IND_RA).
  • IND_RA indifferent electrode
  • a unipolar endocardial RA lead could be substituted for the depicted bipolar endocardial RA lead 16 and be employed with the IND_CAN electrode 20.
  • one of the distal tip RA pace/sense electrode 19 and proximal ring RA pace/sense electrode 21 can be employed with the
  • IND_CAN electrode 20 for unipolar pacing and/or sensing.
  • Endocardial RV lead 32 is passed through the vein and the RA chamber of the heart 10 and into the RV where its distal ring and tip RV pace/sense electrodes 38 and 40 are fixed in place in the apex by a conventional distal attachment mechanism 41 .
  • the RV lead 32 is formed with an in-line connector 34 fitting into a bore of ICD connector block 12 that is coupled to electrically insulated conductors within lead body 36 and connected with distal tip RV pace/sense electrode 40 and proximal ring RV pace/sense electrode 38, wherein the proximal ring RV pace/sense electrode 38 functions as an indifferent electrode (IND_RV).
  • IND_RV indifferent electrode
  • a unipolar endocardial RV lead could be substituted for the depicted bipolar endocardial RV lead 32 and be employed with the IND_CAN electrode 20, or one of the distal tip RV pace/sense electrode 40 and proximal ring RV pace/sense electrode 38 can be employed with the IND_CAN electrode 20 for unipolar pacing and/or sensing.
  • RV lead 32 further includes an RV coil electrode 42 and a superior vena cava (SVC) coil electrode 44 which are coupled to respective insulated conductors extending within lead body 36 to connector 34 engaged in a bore of ICD connector block 12.
  • SVC superior vena cava
  • RA lead 16 may carry a coil electrode used in delivering a high voltage shock pulse.
  • a transvenous LV CS lead 52 is passed through a vein and the RA chamber of the heart 10, into the ostium of the CS and then inferiorly in a branching vessel of the great vein 48 to extend a pair of distal LV CS pace/sense electrodes 50 and 55 alongside the LV chamber.
  • the LV CS lead may employ a deployable fixation mechanism or may instead rely on the close confinement within these vessels to maintain the pace/sense electrode or electrodes at a desired site.
  • the LV CS lead 52 is coupled at the proximal end connector 54 fitting into a bore of ICD connector block 12.
  • the distal, LV CS pace/sense electrodes 50 and 55 may be paired in a bipolar combination or used in other electrode combinations, e.g., with the proximal ring RV indifferent pace/sense electrode 38 for delivering LV pace pulses across the bulk of the left ventricle and the intra-ventricular septum.
  • the distal LV CS pace/sense electrodes 50 or 55 may also be paired with the distal tip RV pace/sense electrode 40 for sensing across the RV and LV.
  • LV CS lead 52 could bear proximal LA CS pace/sense electrodes 57 and 58 positioned along the lead body 56 for positioning along the LA.
  • the LV CS lead body may be smaller between the proximal LA CS electrodes 57 and 58 and the distal LV CS pace/sense electrodes 50 and 55.
  • Pacing and sensing in the atria may occur using any unipolar or bipolar pair employing at least one of LA CS pace/sense electrodes 57 and 58 and/or one RA pace/sense electrodes 19 and 21 .
  • the electrodes designated above as “pace/sense” electrodes are used for both pacing and sensing functions. These "pace/sense” electrodes can be selected to be used exclusively as pace or sense electrodes or to be used in common as pace/sense electrodes in programmed combinations for sensing cardiac signals and delivering pace pulses along selected pacing and sensing vectors. Separate or shared indifferent pace and sense electrodes can also be designated in pacing and sensing functions. For convenience, the following description separately designates pace and sense electrode pairs where a distinction is appropriate.
  • FIG. 2 is a functional block diagram of the ICD 14 shown in FIG. 1 , according to one embodiment.
  • Circuitry 24, located within ICD 14 of FIG. 1 includes pacing circuitry 25, defibrillation circuitry 26, sensing circuitry 27, control processor 28, memory 29, and communication system 30.
  • Leads 16, 32 and 52 are connected to pacing circuitry 25, defibrillation circuitry 26 and sensing circuitry 27.
  • Each lead (and in turn individual electrodes associated with each lead) coupled to the ICD may be used in multiple capacities to sense cardiac depolarizations (e.g. P-waves and R-waves), deliver pacing pulses, and deliver CV/DF shocks.
  • cardiac depolarizations e.g. P-waves and R-waves
  • Control processor 28 receives input through sensing circuitry 27 from leads 16, 32 and 52 concerning depolarizations sensed by the electrodes connected to leads 16, 32 and 52. Based on input received from sensing circuitry 27, control processor 28 performs an arrhythmia detection algorithm for detecting arrhythmias and selecting a therapy as needed. Therapy may include providing ATP therapy using pacing circuitry 25 and selected pacing electrodes, providing defibrillation or cardioversion shocks using defibrillation circuitry 26 and a selected high voltage coil electrode, or providing no treatment at all.
  • Control processor 28 stores selected data to memory 29, and retrieves stored data from memory 29 as necessary in performing detection and therapy delivery algorithms and storing data relating to detected arrhythmia episodes.
  • Communication system 30 includes telemetry processor 31 , transmission circuitry 35, receiving circuitry 33, and antenna 37. Communication system 30 allows communication between ICD 14 and devices external to the patient for programming ICD 14 and retrieving data stored by ICD 14.
  • an atrial stimulus interval refers to an interval during which an atrial stimulus pulse is delivered for monitoring a response of the ventricular depolarizations for use in discriminating a cardiac arrhythmia and does not refer to intervals that may be used in delivering therapeutic pacing pulses such as bradycardia pacing pulses.
  • the atrial stimulus interval may be initiated upon sensing an intrinsic ventricular depolarization, an intrinsic (non-paced) atrial depolarization or some combination of both.
  • delivery of the atrial stimulus may be triggered at a defined interval following the ventricular depolarization. It is desirable, however, that the preceding occurrence of an atrial depolarization, paced or sensed, is verified as a precondition of delivery of the stimulation pulse provided to facilitate arrhythmia discrimination.
  • the timing of both the atrial and ventricular depolarizations may be employed to determine the stimulus delivery time or the permitted range of delivery times (i.e., the stimulation time window).
  • the defined intervals chosen for delivery of the stimulus pulses may be pre-programmed by the attending physician based upon an electrophysiological study of the patient, during which myocardial refractory periods may be measured or estimated.
  • the pacemaker itself may determine the optimal stimulus delivery times by varying the stimulus times within the time window and adjusting the defined stimulation intervals to produce the desired result.
  • the desired result may be, for example, a lowering of the ventricular rate.
  • Activation of atrial stimulation for tachycardia discrimination may be triggered by the ICD in response to detecting a fast ventricular rate.
  • the fast ventricular rate may be defined only by a lower rate limit.
  • the fast ventricular rate that activates atrial stimulation may be additionally bounded by an upper rate limit corresponding to a VF lower rate.
  • the fast ventricular rate that activates atrial stimulation may fall into a range that is equal to or faster than a rate associated with a tachycardia detection interval but slower than a VF rate.
  • the fast ventricular rate detected for initiating atrial stimulation may further be associated with 1 :1 correspondence between atrial and ventricular sensed events, making it difficult to discriminate the fast ventricular rate as being associated with a VT or SVT.
  • the atrial stimulation pulses may be deactivated in response to a slowing of the ventricular rate or if the detected ventricular rate accelerates or becomes hemodynamically unstable.
  • the determination of whether the ventricular rate has responded to the atrial stimulation pulse(s) may be made by comparing the ventricular cycle lengths (ventricular cycle lengths) prior to atrial stimulation to a ventricular cycle length occurring when an atrial stimulus pulse is delivered.
  • FIG. 3 is a functional flowchart 100 illustrating the operation of an ICD practicing one embodiment for arrhythmia discrimination.
  • Flow chart 100 is intended to illustrate the functional operation of the device, and should not be construed as reflective of a specific form of software or hardware necessary to practice the methods described. It is believed that the particular form of software will be determined primarily by the particular system architecture employed in the device and by the particular detection and therapy delivery methodologies employed by the device. Providing software to accomplish the described functionality in the context of any modern ICD, given the disclosure herein, is within the abilities of one of skill in the art.
  • “computer-readable medium” includes but is not limited to any volatile or non- volatile media, such as a RAM, ROM, CD-ROM, NVRAM, EEPROM, flash memory, and the like.
  • the instructions may be implemented as one or more software modules, which may be executed by themselves or in combination with other software.
  • the operation of the ICD to provide atrial stimulation for arrhythmia discrimination is controlled by the microprocessor responsive to software stored in memory, comprising instructions for causing the ICD to perform the described functions.
  • the ICD detects a fast ventricular rate at block 102.
  • the fast ventricular rate may be detected according to any preferred arrhythmia detection algorithm implemented in the ICD and is not limited to any particular rate detection method or criteria.
  • a required number of ventricular cycle lengths (RR intervals) must be less than a tachycardia detection interval, e.g. 9 out of 12 of the most recent vetricular cycle lenghts must be less than a VT detection interval, in order to detect a fast ventricular rate.
  • a fast ventricular rate that is suspected of possibly arising from an SVT may correspond to a venticular cycle lenght range defined by a maximum possible venticular cycle length interval and a minimum ventricular cycle length associated with SVT.
  • Ventricular cycle lengths shorter than the minimum ventricular cycle length may be automatically detected as VT or VF and followed appropriately by delivery of ventricular anti-tachycardia pacing (ATP) or cardioversion/defibrillation (CV/DF) shock.
  • ATP ventricular anti-tachycardia pacing
  • CV/DF cardioversion/defibrillation
  • Additional criteria may be required to be satisfied at block 102 in order to detect a fast ventricular rate that triggers atrial stimulation for tachycardia discrimination.
  • other criteria may relate to factors that make the fast ventricular rate difficult to distinguish from an SVT.
  • a fast ventricular rate may be suspected of being SVT when indiscriminate R-wave morphology or 1 :1 P-wave to R-wave correspondence is identified.
  • other requirements that may be applied at block 102 in detecting a fast ventricular rate that activates atrial stimulation for arrhythmia discrimination may include morphology or event pattern- based criteria.
  • the fast ventricular rate may be a suspected SVT causing activation of atrial stimulation.
  • the ratio of sensed atrial P-waves to sensed ventricular R-waves are in 1 :1 correspondence, and a fast ventricular rate is detected, atrial stimulation for tachycardia stimulation is activated.
  • an atrial stimulus interval is set at block 104 to deliver atrial stimulus pulses during the window of time in which the ventricles are still in refractory and the atria are not, on one or more cardiac beats.
  • the atrial stimulus interval may be in timed relation to a ventricular sense event and/or an atrial sense event as described above.
  • the atrial stimulus interval may be timed based on measured refractory periods in an individual patient or based on clinical data from a population of patients.
  • At block 106 atrial stimulation pulses are delivered, carefully timed to occur during ventricular refractory period for resetting the SA node or blocking AV node conduction.
  • the atrial stimulation pulses may include a single pulse per cardiac cycle or a train of pulses per cardiac cycle and may be delivered for a single cardiac cycle or a predetermined number of cardiac cycles, e.g. on the order of approximate 3 to 10 cardiac cycles, to allow the ventricular response to the atrial stimulus pulse(s) to be measured at block 108.
  • a single pulse when properly timed and delivered at an appropriate location, can be effective in causing a slowing of the ventricular rate during an SVT.
  • a train of pulses may be delivered at block 106 during a window of time expected to be within the ventricular refractory period and outside the atrial refractory period.
  • An exact timing of a single atrial stimulus pulse for achieving SA node reset or AV node block may vary with heart rate, electrode location, between patients, and with other factors.
  • an atrial stimulus pulse or a train of pulses may be delivered at more than one location in the atria at the same time or at slightly different times.
  • a ventricular response to the atrial stimulus pulses will be detected.
  • a ventricular response will be a slowing of the ventricular rate which can be measured as an increase in ventricular cycle lengths or detecting a change in the ratio of atrial to ventricular sensed depolarizations.
  • the fast ventricular rate is arising from the ventricles, i.e. a true VT, no ventricular response to the atrial stimulus pulses will be detected at block 108.
  • the ventricular rate may accelerate during atrial stimulation if the VT worsens. In other cases, the ventricular rate will remain relatively unchanged during atrial stimulation.
  • the ventricular cycle length is measured during each cardiac cycle associated with an atrial stimulus pulse at block 108.
  • An average, maximum, minimum or range of ventricular cycle lengths associated with an atrial stimulus pulse may be measured and compared, at block 1 10, to an average, minimum or range of ventricular cycle lengths measured prior to delivering atrial stimulus pulses and contributing to the detection of the fast ventricular rate.
  • the ventricular cycle lengths occurring during atrial stimulation may be compared to predefined ventricular tachycardia detection intervals at block 1 10 to determine if the ventricular cycle lengths become longer than a tachycardia detection interval.
  • VT therapy is delivered at block 1 14 according to a programmed therapy delivery menu.
  • depolarizations to atrial depolarizations is determined at block 108 for detecting a decrease in the ventricular rate at block 1 10. If the atrial stimulus pulse causes a resetting of the SA node or AV node block, a 1 :2 ratio, or other changed ratio, of ventricular to atrial depolarizations will occur. The atrial depolarization associated with the atrial stimulus pulse will not be conducted to the ventricles whereas the next intrinsic atrial depolarization arising from the SA node will conduct to the ventricles. In some cases, the ratio of ventricular to atrial depolarization may change from 1 :1 during a conducted fast ventricular rate to, for example, 1 :3 or even 2:3, during atrial stimulus delivery depending on the duration and stability of the refractory periods.
  • monitoring the ventricular response at block 108 may include monitoring a ratio of atrial and ventricular depolarization events. Detecting a decrease in the ventricular rate at block 1 10 in response to an atrial stimulus pulse includes detecting more than one atrial depolarization during a ventricular cycle length associated with an atrial stimulus pulse delivered therein.
  • an examination of R-wave morphology, a change in P-R intervals, or change in a conduction sequence as determined from EGM signals sensed at different myocardial sites may be useful in distinguishing R- waves that are conducted from an atrial stimulus pulse or conducted from an intrinsic atrial event.
  • the response monitored at block 108 may include measurements of P-R intervals and/or EGM morphology analysis at one or more ventricular sensing sites.
  • delivery of one or more atrial stimulus pulses may effectively terminate an SVT. Termination of a SVT in response to the atrial stimulus will also result in a slowing of the ventricular rate (which can be detected at block 1 10) when the fast ventricular rate was being conducted from the atria. As such, the detection of SVT is made at block 1 16 and VT therapy is withheld at block 1 18 when atrial stimulus pulses cause a termination of the SVT.
  • FIG. 4 is a flow chart 200 of an alternative embodiment of a method for discriminating cardiac events.
  • blocks 102 through 1 18 correspond to identically numbered blocks shown in FIG. 3.
  • the parameters of the individual atrial stimulation pulses (width, amplitude, etc.) will be determined at implant and programmed into the ICD memory by the attending physician.
  • the parameters of the individual atrial stimulation pulses width, amplitude, etc.
  • an atrial stimulus interval may be adjusted during a tachycardia episode if no ventricular response is detected during delivery of one or more atrial stimulus pulses.
  • adjustments to the atrial stimulus may be made to further verify that the fast ventricular rate is not being conducted from atrial tissue. Adjustments to the atrial stimulus may include changing a pulse delivery electrode, changing a pulse amplitude, width or pulse number.
  • the atrial stimulus interval may be adjusted at block 204 when no ventricular response to atrial stimulation is detected.
  • the atrial stimulus interval (or another atrial stimulus parameter) is adjusted at block 204.
  • the atrial stimulus interval may be adjusted one or more times within the range of the above-discussed stimulus time window to promote delivery of the stimulus pulse(s) during ventricular refractory and outside atrial refractory for effective resetting of the SA node and/or AV node block.
  • the atrial stimulus interval may be increased (or decreased) in predetermined increments, e.g. 10 ms, on successive cardiac beats.
  • the ventricular response is monitored to determine if, on any one or more beats during atrial stimulus delivery, a slowing of the ventricular rate is detected. If the fast ventricular rate is a true VT, it is desirable to make that determination in as short as time as possible.
  • variable atrial stimulus interval on a series of successive beats to effectively "scan" the expected window of time that is outside atrial refractory but within ventricular refractory and determine if any ventricular response to a properly timed atrial stimulus within the window can be achieved.
  • the atrial stimulus interval may be increased or decreased on each successive beat, every other beat, every third beat, etc. to allow the ventricular response to successive adjustments of the atrial stimulus interval to be monitored. If a ventricular response is detected during the successive adjustments, the atrial stimulus may be terminated before all increments or decrements are applied, and an SVT detected.
  • VT is detected at block 1 12.
  • a VT therapy is delivered at block 1 14.

Landscapes

  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Electrotherapy Devices (AREA)

Abstract

La présente invention concerne un appareil permettant de distinguer des événements cardiaques, par la détection de dépolarisations atriales et ventriculaires suivies de périodes réfractaires associées. Un rythme ventriculaire rapide est détecté (102) en réponse aux dépolarisations ventriculaires détectées. En réponse à la détection du rythme ventriculaire rapide, au moins une impulsion de stimulus est administrée (106) au tissu atrial pendant la période réfractaire associée du ventricule, mais en dehors d'une période réfractaire associée du tissu atrial stimulé. Une réponse ventriculaire à l'impulsion de stimulus de tissu atrial est déterminée (108), et l'événement cardiaque est distingué (110) sur la base de la réponse ventriculaire à l'impulsion de stimulus de tissu atrial.
PCT/US2012/022505 2011-03-09 2012-01-25 Appareil permettant de distinguer une tachycardie supraventriculaire d'une tachycardie ventriculaire au moyen d'une stimulation myocardique focale WO2012121810A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161450870P 2011-03-09 2011-03-09
US61/450,870 2011-03-09
US13/357,659 2012-01-25
US13/357,659 US20120232606A1 (en) 2011-03-09 2012-01-25 Using focal myocardial stimulation to distinguish supraventricular tachycardia from ventricular tachycardia

Publications (1)

Publication Number Publication Date
WO2012121810A1 true WO2012121810A1 (fr) 2012-09-13

Family

ID=46796556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/022505 WO2012121810A1 (fr) 2011-03-09 2012-01-25 Appareil permettant de distinguer une tachycardie supraventriculaire d'une tachycardie ventriculaire au moyen d'une stimulation myocardique focale

Country Status (1)

Country Link
WO (1) WO2012121810A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0597459A2 (fr) * 1992-11-13 1994-05-18 Masood Akhtar Appareil implantable de cardioversion et/ou de défibrilllation pour la correction des tachycardies
US20060058849A1 (en) * 2000-11-14 2006-03-16 Cardiac Pacemakers, Inc. Method and apparatus for using atrial discrimination algorithms to determine optimal pacing therapy and therapy timing
US20090259269A1 (en) * 2008-04-09 2009-10-15 Brown Mark L Method and apparatus for detecting and treating tachyarrhythmias incorporating diagnostic/therapeutic pacing techniques
US20100249627A1 (en) * 2009-03-31 2010-09-30 Xusheng Zhang Detecting A Condition Of A Patient Using A Probability-Correlation Based Model

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0597459A2 (fr) * 1992-11-13 1994-05-18 Masood Akhtar Appareil implantable de cardioversion et/ou de défibrilllation pour la correction des tachycardies
US20060058849A1 (en) * 2000-11-14 2006-03-16 Cardiac Pacemakers, Inc. Method and apparatus for using atrial discrimination algorithms to determine optimal pacing therapy and therapy timing
US20090259269A1 (en) * 2008-04-09 2009-10-15 Brown Mark L Method and apparatus for detecting and treating tachyarrhythmias incorporating diagnostic/therapeutic pacing techniques
US20100249627A1 (en) * 2009-03-31 2010-09-30 Xusheng Zhang Detecting A Condition Of A Patient Using A Probability-Correlation Based Model

Similar Documents

Publication Publication Date Title
US7515959B2 (en) Delivery of CRT therapy during AT/AF termination
EP1684864B1 (fr) Apport therapeutique sur et efficace pour moteur de stimulation cardiaque extra systolique
JP4343107B2 (ja) 過駆動ペーシングを用いて連続的に発生する不整脈を予防する方法および装置
US7574258B2 (en) Cardiac therapy triggered by capture verification
JP4440781B2 (ja) 不整脈を鑑別するためにａｔｐ戻り周期長を用いる装置および方法
US6195584B1 (en) Method and apparatus for determining atrial lead dislocation
JP2005529690A5 (fr)
US7386343B1 (en) Spectrum-driven arrhythmia treatment method
US7130685B2 (en) Method to prevent pacemaker induced non-reentrant VA synchrony using adaptive atrial pacing output
US20040127946A1 (en) Method and apparatus for atrial tachyarrhythmia cardioversion
US6889083B2 (en) Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
WO2005105205A1 (fr) Methode et appareil de commande de l'administration des pulsations d'entrainement electrosystolique en reponse a une frequence ectopique accrue
WO2003090859A1 (fr) Securite de la stimulation biventriculaire
US10293155B2 (en) Identify insulation breach using electrograms
US8135464B1 (en) Painless ventricular rate control during supraventricular tachycardia
JP5017458B2 (ja) 房室遅延調整の無効化
US9144685B2 (en) Using focal myocardial stimulation to distinguish supraventricular tachycardia from ventricular tachycardia
WO2012121810A1 (fr) Appareil permettant de distinguer une tachycardie supraventriculaire d'une tachycardie ventriculaire au moyen d'une stimulation myocardique focale
US8233978B1 (en) Method and device for switching between arrhythmia prevention modes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12702382

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12702382

Country of ref document: EP

Kind code of ref document: A1